Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Down 39.3% in July

Addex Therapeutics Ltd (NASDAQ:ADXN) was the recipient of a large decrease in short interest in the month of July. As of July 15th, there was short interest totalling 1,700 shares, a decrease of 39.3% from the June 30th total of 2,800 shares. Based on an average trading volume of 8,100 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.2% of the company’s shares are sold short.

Addex Therapeutics Stock Performance

ADXN stock opened at $8.00 on Friday. The company has a market capitalization of $8.48 million, a P/E ratio of -0.46 and a beta of 1.77. Addex Therapeutics has a 52-week low of $5.00 and a 52-week high of $27.90. The company has a fifty day moving average price of $8.36 and a 200-day moving average price of $10.77.

Addex Therapeutics (NASDAQ:ADXN) last released its quarterly earnings results on Thursday, June 6th. The company reported ($1.37) earnings per share (EPS) for the quarter. The firm had revenue of $0.27 million for the quarter. Addex Therapeutics had a negative return on equity of 364.24% and a negative net margin of 818.50%. As a group, sell-side analysts forecast that Addex Therapeutics will post -11.8 earnings per share for the current fiscal year.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.